[go: up one dir, main page]

PE20140699A1 - FORMULATION OF A COMPLEX INCLUDING LERCANIDIPINE HYDROCHLORIDE AND VALSARTAN AND METHOD FOR THE PREPARATION OF THE SAME - Google Patents

FORMULATION OF A COMPLEX INCLUDING LERCANIDIPINE HYDROCHLORIDE AND VALSARTAN AND METHOD FOR THE PREPARATION OF THE SAME

Info

Publication number
PE20140699A1
PE20140699A1 PE2013001346A PE2013001346A PE20140699A1 PE 20140699 A1 PE20140699 A1 PE 20140699A1 PE 2013001346 A PE2013001346 A PE 2013001346A PE 2013001346 A PE2013001346 A PE 2013001346A PE 20140699 A1 PE20140699 A1 PE 20140699A1
Authority
PE
Peru
Prior art keywords
valsartan
preparation
formulation
same
hydrochloride
Prior art date
Application number
PE2013001346A
Other languages
Spanish (es)
Inventor
Young Sik Chung
Soo Ah Park
Ree Sun Kim
Jae Hyeon Juhn
Dong Kyu Kim
Yoo Rin Kim
Hee Dong Park
Seong Jae Park
Sung Hack Lee
Ju Hyun Kim
Min Young Jung
Original Assignee
Lg Life Sciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46207595&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20140699(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lg Life Sciences Ltd filed Critical Lg Life Sciences Ltd
Publication of PE20140699A1 publication Critical patent/PE20140699A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

REFERIDA A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE COMO PRINCIPIOS ACTIVOS AL CLORHIDRATO DE LERCANIPINA Y AL VALSARTAN, LOS CUALES SE ENCUENTRAN SEPARADOS Y EN FORMA GRANULAR, DONDE LOS GRANULOS DEL CLORHIDRATO DE LERCANIDIPINA COMPRENDEN DE 4 A 10 PARTES EN PESO DE UN EXCIPIENTE FARMACEUTICAMENTE ACEPTABLE POR 1 PARTE EN PESO DE CLORHIDRATO DE LERCANIDIPINA Y LOS DEL VALSARTAN COMPRENDEN DE 1 A 2 PARTES EN PESO DE UN EXCIPIENTE POR 1 PARTE DE VALSARTAN. TAMBIEN ESTA REFERIDA A UN PROCEDIMIENTO DE PREPARACION. DICHA COMPOSICION ES UTIL EN EL TRATAMIENTO DE ANGINA DE PECHO, HIPERTENSION, ARTERIOESPASMO, ENTRE OTROSREFERRED TO A PHARMACEUTICAL COMPOSITION THAT INCLUDES LERCANIPINE HYDROCHLORIDE AND VALSARTAN AS ACTIVE PRINCIPLES, WHICH ARE SEPARATED AND IN GRANULAR FORM, WHERE THE LERCANIPINE HYDROCHLORIDE GRANULES INCLUDE ONE PORTION OF 1 PORTICAL PART OF FORMER 10 PART BY WEIGHT OF LERCANIDIPINE HYDROCHLORIDE AND THOSE OF VALSARTAN INCLUDE 1 TO 2 PARTS BY WEIGHT OF AN EXCIPIENT PER 1 PART OF VALSARTAN. IT IS ALSO REFERRED TO A PREPARATION PROCEDURE. SUCH COMPOSITION IS USEFUL IN THE TREATMENT OF ANGINA PECTORIS, HYPERTENSION, ARTERIOSPASM, AMONG OTHERS

PE2013001346A 2010-12-09 2011-12-07 FORMULATION OF A COMPLEX INCLUDING LERCANIDIPINE HYDROCHLORIDE AND VALSARTAN AND METHOD FOR THE PREPARATION OF THE SAME PE20140699A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR20100125804 2010-12-09

Publications (1)

Publication Number Publication Date
PE20140699A1 true PE20140699A1 (en) 2014-06-13

Family

ID=46207595

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2013001346A PE20140699A1 (en) 2010-12-09 2011-12-07 FORMULATION OF A COMPLEX INCLUDING LERCANIDIPINE HYDROCHLORIDE AND VALSARTAN AND METHOD FOR THE PREPARATION OF THE SAME

Country Status (18)

Country Link
EP (1) EP2648730A4 (en)
KR (1) KR101414814B1 (en)
CN (1) CN103249415B (en)
AR (1) AR084195A1 (en)
AU (1) AU2011339150B2 (en)
BR (1) BR112013013415A2 (en)
CL (1) CL2013001626A1 (en)
CO (1) CO6721030A2 (en)
DO (1) DOP2013000115A (en)
EA (1) EA201390844A1 (en)
IL (1) IL226449A0 (en)
MX (1) MX2013005716A (en)
PE (1) PE20140699A1 (en)
PH (1) PH12013500980A1 (en)
SG (1) SG190326A1 (en)
UA (1) UA108277C2 (en)
UY (1) UY33772A (en)
WO (1) WO2012077968A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102755322B (en) * 2012-07-24 2013-12-11 兆科药业（广州）有限公司 Compound preparation of lercanidipine and atorvastatin
CN105163734A (en) * 2013-03-12 2015-12-16 株式会社Lg生命科学 Composite preparation containing valsartan and rosuvastatin calcium and its manufacturing method
US11382866B2 (en) * 2017-07-06 2022-07-12 Mankind Pharma Ltd. Fixed dose pharmaceutical composition of valsartan and sacubitril
KR102233986B1 (en) * 2019-06-25 2021-03-30 경남과학기술대학교 산학협력단 Solid pharmaceutical composition comprising lafutidine and irsogladin and process for producing thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040198789A1 (en) * 2003-02-28 2004-10-07 Recordati Ireland Limited Lercanidipine/ARB/diuretic therapeutic combinations
US20070105912A1 (en) * 2003-12-01 2007-05-10 Per Holm Pharmaceutical compositions comprising lercanidipine
WO2007001067A2 (en) * 2005-06-27 2007-01-04 Daiichi Sankyo Company, Limited Solid dosage form comprising an angiotensin ii receptor antagonist and a calcium channel blocker
KR100888131B1 (en) * 2006-10-10 2009-03-11 한올제약주식회사 Combination preparation for Cardiovascular disease therapy by Chronotherapy theory.

Also Published As

Publication number Publication date
MX2013005716A (en) 2013-06-12
EP2648730A4 (en) 2014-08-06
CO6721030A2 (en) 2013-07-31
SG190326A1 (en) 2013-06-28
PH12013500980A1 (en) 2013-07-08
KR101414814B1 (en) 2014-07-21
DOP2013000115A (en) 2014-07-31
CN103249415B (en) 2017-12-12
AU2011339150A1 (en) 2013-06-06
AR084195A1 (en) 2013-04-24
KR20120089787A (en) 2012-08-13
EA201390844A1 (en) 2013-11-29
IL226449A0 (en) 2013-07-31
WO2012077968A3 (en) 2012-07-26
CL2013001626A1 (en) 2013-10-04
UY33772A (en) 2012-07-31
CN103249415A (en) 2013-08-14
BR112013013415A2 (en) 2019-09-24
EP2648730A2 (en) 2013-10-16
AU2011339150B2 (en) 2015-09-10
WO2012077968A2 (en) 2012-06-14
UA108277C2 (en) 2015-04-10

Similar Documents

Publication Publication Date Title
AR125013A2 (en) METHOD FOR IMPROVING THE SOLUBILITY OF A SUBSTANCE WHICH IS 9-ETHYL-6,6-DIMETHYL-8-(4-MORFOLIN-4-IL-PIPERIDIN-1-IL)-11-OXO-6,11-DIHYDRO-5H- BENZO[B]CARBAZOLE-3-CARBONITRILE OR A SALT THEREOF
CL2014000504A1 (en) Compounds derived from substituted condensed pyrimidines; preparation procedure; pharmaceutical composition; and use in the treatment and / or prevention of heart failure, angina pectoris, hypertension, among other diseases.
GT201400111A (en) SUBSTITUTED TRIAZOLOPIRIDINS
AR089578A1 (en) COMPOSITIONS, METHODS TO TREAT HEPATITIS C VIRUS AND PREPARATION PROCESS
TN2014000030A1 (en) Tetrahydropyrido-pyridine and tetrahydropyrido-pyrimidine compounds and use thereof as c5a receptor modulators
CY1119798T1 (en) FORM IV IV Hydrochloride Ibabradine
CL2017002792A1 (en) Amido substituted cyclohexane derivatives
EA201391000A1 (en) INDOL CONNECTIONS OR THEIR ANALOGUES USEFUL FOR THE TREATMENT OF AGE MAKULAR DEGENERATION (AMD)
CL2013003598A1 (en) Compounds derived from benzooxazepinone, sodium channel modulators; pharmaceutical composition comprising them; and its use in the treatment of selected diseases of arrhythmias, heart failure, angina, myocardial infarction, diabetes, among others
CR20140508A (en) MODULATORS OF THE ROUTE OF THE COMPLEMENT AND USES OF THE SAME
CL2014001779A1 (en) Compounds derived from substituted fused pyrimidines and triazines; preparation procedure; Pharmaceutical composition and its use in the treatment and / or prevention of heart failure, angina pectoris, hypertension, among other diseases.
CO6741217A2 (en) Modular glucagon receptor
UY33183A (en) INHIBITING COMPOUNDS OF VIRUS FLAVIVIRIDAE, PHARMACEUTICAL COMPOSITION THAT CONTAINS THEM AND ITS USE IN THE MANUFACTURE OF A MEDICINAL PRODUCT
MX377410B (en) INTEGRIN RECEPTOR ANTAGONISTS AND THEIR METHODS OF USE.
GT201500053A (en) PHARMACEUTICAL COMPOSITION COVERED WITH REGORAFENIB
ECSP12012270A (en) PIRAZOL COMPOUNDS AS INHIBITORS OF THE SIGMA RECEIVER
AR098415A1 (en) COMPOSITE FORMULATION THAT INCLUDES TADALAFIL AND AMLODIPINE
EA201690679A1 (en) STABLE PHARMACEUTICAL COMPOSITION CONTAINING AMLODIPIPIN AND VALSARTAN
CL2009001016A1 (en) Solid pharmaceutical preparation with delayed release comprising: a) a pharmaceutically active ingredient, b) 15 to 40% by weight of a mixture of polyvinylpyrrolidone and / or a derivative of polyvinylpyrrolidone and c) at least one diluent.
CO6741223A2 (en) Azetidine derivatives useful for the treatment of metabolic and inflammatory diseases
GT201500035A (en) ORAL PHARMACEUTICAL COMPOSITION IN THE FORM OF MICROSPHERES AND ELABORATION PROCESS
CL2011003371A1 (en) Solid and stable oral fixed dose pharmaceutical composition comprising irbesartan, amlodipine besilate and excipients; preparation procedures; use in the treatment of hypertension.
PE20141669A1 (en) SELECTIVE ANDROGEN RECEIVER MODULATORS
CO2019011547A2 (en) Novel solid crystalline compound of 3-phenyl-4-propyl-1- (pyridin-2-yl) -1h-pyrazol-5-ol hydrochloride
PE20140699A1 (en) FORMULATION OF A COMPLEX INCLUDING LERCANIDIPINE HYDROCHLORIDE AND VALSARTAN AND METHOD FOR THE PREPARATION OF THE SAME

Legal Events

Date Code Title Description
FC Refusal